Plasma Selenium Concentrations Are Sufficient and Associated with Protease Inhibitor Use in Treated HIV-Infected Adults

摘要: Background: Selenium is an essential constituent of selenoproteins, which play a substantial role in antioxidant defense and inflammatory cascades. deficiency associated with disease states characterized by inflammation, including cardiovascular (CVD). Although HIV infection has been low selenium, the selenium status HIV-related CVD unclear. Objectives: We sought to assess associations between plasma markers immune activation, subclinical vascular HIV-infected adults on contemporary antiretroviral therapy (ART) determine if statin modifies status. Methods: In Stopping Atherosclerosis Treating Unhealthy bone RosuvastatiN trial, stable ART were randomly assigned 1:1 rosuvastatin or placebo. Plasma concentrations determined at entry, week 24, 48. Spearman correlation linear regression analyses used relations baseline factors disease. Changes over 24 48 wk compared groups. Results: One hundred forty-seven included. All participants ART. Median current CD4+ count was 613, 76% had HIV-1 RNA ≤48 copies/mL (range: <20–600). concentration 122 μg/L 62–200). At baseline, higher protease inhibitor (PI) use, lower body mass index, proportion activated CD8+ T cells (CD8+CD38+human leukocyte antigen-DR+), but not inflammation Over wk, increased group (P < 0.01 within group), change did differ groups (+13.1 vs. +5.3 μg/L; P = 0.14 groups). Conclusions: normal range for background population The association PI use may have implications allocation, especially resource-limited countries. Also, it appears that increase concentrations; however, larger studies are necessary confirm this finding. This trial registered clinicaltrials.gov as {"type":"clinical-trial","attrs":{"text":"NCT01218802","term_id":"NCT01218802"}}NCT01218802.